Arixtra (fondaparinux) vs. lovenox (enoxaparin) in prevention of deep vein thrombosis in acute medically ill, non-surgical patients.

Trial Profile

Arixtra (fondaparinux) vs. lovenox (enoxaparin) in prevention of deep vein thrombosis in acute medically ill, non-surgical patients.

Discontinued
Phase of Trial: Phase II

Latest Information Update: 08 Dec 2017

At a glance

  • Drugs Enoxaparin sodium (Primary) ; Fondaparinux sodium (Primary)
  • Indications Deep vein thrombosis
  • Focus Adverse reactions
  • Acronyms BRiEF
  • Most Recent Events

    • 08 Jul 2011 Status changed from recruiting to discontinued as reported by ClinicalTrials.gov.
    • 13 Dec 2007 Status changed from initiated to recruiting.
    • 03 Sep 2007 New trial record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top